Compare SIG & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIG | TLX |
|---|---|---|
| Founded | 1950 | 2015 |
| Country | Bermuda | Australia |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 1997 | 2024 |
| Metric | SIG | TLX |
|---|---|---|
| Price | $100.26 | $11.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $111.14 | $21.13 |
| AVG Volume (30 Days) | ★ 754.3K | 155.5K |
| Earning Date | 06-02-2026 | 08-19-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 974.07 | N/A |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $6,247,100,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $1.71 | N/A |
| P/E Ratio | ★ $131.29 | $150.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $71.62 | $6.28 |
| 52 Week High | $110.20 | $12.48 |
| Indicator | SIG | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 55.50 |
| Support Level | $80.87 | $10.12 |
| Resistance Level | $100.46 | $12.35 |
| Average True Range (ATR) | 3.47 | 0.25 |
| MACD | 1.85 | 0.04 |
| Stochastic Oscillator | 77.54 | 66.96 |
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.